Singh Kanwar Samrat, Ashok B K, Kaur Mandip, Ravishankar B, Chandola Hari Mohan
Department of Kayachikitsa, SKSS Ayurvedic College, Sarabha, Ludhiana, Punjab, India.
Research and Development, The Himalaya Drug Company, Bengaluru, Karnataka, India.
Ayu. 2014 Apr;35(2):187-90. doi: 10.4103/0974-8520.146248.
Diabetes mellitus is a persistent health problem that requires innovative strategies to improve health and needs a multifactorial approach for the treatment. Saptarangyadi Ghanavati, a formulated Ayurvedic compound consists of herbs with anti-diabetic potential.
To evaluate the hypoglycemic and antihyperglycemic activities of Saptarangydi Ghanavati.
For hypoglycemic activity 18 Swiss albino mice were divided into three groups (6 in each). First group served as normal control, second group is the test drug and third is the standard control group. For antihyperglycemic activity 24 Swiss albino mice were divided into four groups (6 in each). First group served as water control, second negative control, third test drug and fourth as standard control group. Test drug Saptarangydi Ghanavati was suspended in water and administered to animals at the dose of 400 mg/kg. Glibenclamide was used as reference standard in both the models at the dose of 0.65 mg/kg.
Saptarangyadi Ghanavati showed mild reduction in Blood Sugar Level (BSL) at all the time intervals in normoglycemic mice; however, the observed decrease of BSL was found to be statistically non significant. In antihyperglycemic activity, even though the drug failed to cease the hyperglycemia in the first hour after the glucose overload, it attenuated the same in later hours in nonsignificant extent.
The study reveals that Saptarangydi Ghanavati has moderate hypoglycemic and antihyperglycemic effect.
糖尿病是一个持续存在的健康问题，需要创新策略来改善健康状况，且治疗需要采取多因素方法。Saptarangyadi Ghanavati是一种配制的阿育吠陀化合物，由具有抗糖尿病潜力的草药组成。
评估Saptarangydi Ghanavati的降血糖和抗高血糖活性。
为进行降血糖活性研究，将18只瑞士白化小鼠分为三组（每组6只）。第一组作为正常对照组，第二组为受试药物组，第三组为标准对照组。为进行抗高血糖活性研究，将24只瑞士白化小鼠分为四组（每组6只）。第一组作为水对照组，第二组为阴性对照组，第三组为受试药物组，第四组为标准对照组。受试药物Saptarangydi Ghanavati悬浮于水中，以400 mg/kg的剂量给予动物。在两个模型中，均使用格列本脲作为参考标准，剂量为0.65 mg/kg。
Saptarangyadi Ghanavati在正常血糖小鼠的所有时间间隔均显示血糖水平（BSL）有轻度降低；然而，观察到的BSL降低在统计学上无显著意义。在抗高血糖活性方面，尽管该药物在葡萄糖负荷后第一小时未能阻止高血糖，但在随后几小时以不显著的程度减轻了高血糖。
该研究表明Saptarangydi Ghanavati具有中度降血糖和抗高血糖作用。
